According to the Washington Post, “Under a major change laid out by Health and Human Services Secretary Alex Azar and drafted as a new federal rule, drug manufacturers would need to disclose in ads the list price of a 30-day supply of any drug that is covered through Medicare and Medicaid and costs more than $35 a month.”
“AHF fully endorses HHS Secretary Azar’s proposed new rule requiring drug price disclosures by the industry in most, if not nearly all drug advertising,” said Michael Weinstein, president of AIDS Healthcare Foundation. “For too long, this industry has run roughshod over the American public with its secretive, and increasingly exorbitant pricing and policies, aided and abetted by Washington politicians it lobbies and lards with campaign contributions. The administration’s effort here to try and promote some measure of greater transparency on drug pricing by requiring drug manufacturers that serve and supply Medicare and Medicaid patients deserves widespread public, and full congressional support.”
The Post also reported, “The draft rule will now be debated through the fall, and its likelihood of becoming an actual requirement will hinge, in large part, on the intensity of the industry’s resistance.”
